STANDEX Reports Strong Q2 Operational Growth; H1 EPS Impacted by Non-Cash NCI Re-measurement
Summary
Standex reported strong Q2 sales and operating income growth, but its six-month EPS declined due to a non-cash re-measurement of redeemable noncontrolling interest. The company continues restructuring efforts and noted executive 10b5-1 trading plans.
Key Events
-
Strong Q2 Operational Performance
Net sales increased by 16.6% to $221.3 million for the three months ended December 31, 2025, and operating income surged by 320.3% to $35.6 million, driven by organic growth and acquisitions.
-
H1 EPS Impacted by Non-Cash Adjustment
Diluted EPS for the six months ended December 31, 2025, decreased by 10.7% to $1.42, primarily due to an $18 million non-cash re-measurement adjustment of redeemable noncontrolling interest.
-
Ongoing Restructuring Initiatives
The company incurred $0.4 million in restructuring costs for the quarter and $6.4 million for the six-month period, related to facility rationalizations and site closures in the Engraving segment, with expected completion by fiscal year 2027.
-
Executive 10b5-1 Trading Plans Adopted
CEO David A. Dunbar adopted a 10b5-1 plan to sell 15,000 shares, and Thomas E. Chorman adopted a plan to sell 500 shares, both commencing in February 2026.
Analysis
Standex International reported robust operational performance for the second quarter and first half of fiscal year 2026. Net sales increased by 16.6% for the quarter and 21.8% for the six-month period, driven by organic growth and recent acquisitions. Operating income saw a substantial rise of 320.3% for the quarter and 100.3% for the six-month period, reflecting higher volume, pricing initiatives, and productivity improvements. However, diluted earnings per share for the six months ended December 31, 2025, decreased by 10.7% compared to the prior year. This decline is primarily due to a significant non-cash re-measurement adjustment of $18 million related to redeemable noncontrolling interest, which reduced net income attributable to common stockholders. The company also continues with restructuring initiatives aimed at cost reduction and productivity, and two executives adopted Rule 10b5-1 trading plans for future share sales.
At the time of this filing, SXI was trading at $240.00 on NYSE in the Technology sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $128.85 to $263.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.